Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.
COVID-19 and metallic taste: Study connects immunoglobulin levels to sensory impairment
Researchers investigated whether COVID-19-related sensory deficiencies are associated with transcriptome changes in the foliate papillae area of the tongue.
July 9, 2024